Zelira Therapeutics (ASX:ZLD) has secured US$33 million (before costs) through a strategic fundraising with TGC Biotechnology Fund, into its HOPE 1 special purpose vehicle, bringing total equity raised to US$36.6 million.
Vitasora Health (ASX:VHL) has completed its $11 million capital raise, following the full receipt of a $6.8 million cornerstone investment at a placement price of $0.03 per share.
Sonic Healthcare's (ASX:SHL) new CEO, Jim Newcombe, is facing investor pressure to reconsider the company’s US operations as he steps into the shoes of long-serving predecessor Colin Goldschmidt.
Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX), a global leader in 3D-printed biomimetic and bioresorbable implants, has entered a multi-year exclusive agreement with Majeton to commercialise its dental, orthodontic, and maxillofacial products across China, Hong Kong, and Macau.
Proteomics International Laboratories (ASX: PIQ) has secured Canadian patent protection for PromarkerEso, its first-in-class blood test for the early detection of esophageal adenocarcinoma.
Clarity Pharmaceuticals (ASX:CU6) has announced that the SECuRE trial, a Phase 1/2a study of 67Cu-SAR-bisPSMA for metastatic castration-resistant prostate cancer.
Atomo Diagnostics (ASX:AT1) has secured a purchase order worth $502,000 for its HIV self-tests, which will be supplied to an African country in March.
Respiratory imaging technology company 4DMedical (ASX:4DX) has raised $150 million through an institutional placement at $3.80 per share.
Ryman Healthcare (ASX:RYM) reported 375 sales of retirement living occupation right agreements for the quarter ended Dec. 31, 2025.
Rhythm Biosciences (ASX:RHY) has launched its updated geneType colorectal cancer risk assessment test, integrating genetic, clinical, and lifestyle factors to improve early identification of individuals at elevated risk of colorectal cancer.
Mayne Pharma (ASX:MYX) chairman Frank Condella will retire, along with two other directors, as the company moves to reduce the size of its board following a failed acquisition bid by US-based Cosette Pharmaceuticals.
Proteomics International Laboratories (ASX:PIQ) has appointed David Morris as CEO and Managing Director, effective Jan. 19.
